Exploring the relationship between social attachment and dopamine D_2/3 receptor availability in the brains of healthy humans using [¹¹C]-(+)-PHNO

ABSTRACT

Differences in striatal dopamine (DA) function may be related to differences in the degree of social attachment to others. Using positron emission tomography (PET), socially detached persons demonstrate reduced DA D_2/3 receptor (D_2/3R) availability in the striatum. However, previous PET studies have only used antagonist radiotracers for D_2/3R and have not specifically examined regions of interest (ROIs) such as the ventral striatum (VS). In 32 healthy persons, we investigated the relationship between self-reported attachment and DA D_2/3R availability in striatal and extrastriatal ROIs as measured using the agonist radiotracer [¹¹C]-(+)-PHNO. Surprisingly, more social attachment—as measured by the attachment subscale of the temperament and character inventory—was related to less [¹¹C]-(+)-PHNO binding in the VS (r(30) = −.43, p = .01). This relationship held in a subsample who also completed the detachment subscale of the Karolinska Scales of Personality (r(10) = .62, p = .03). However, no relationships were observed with BP_ND in the dorsal striatum or D₃R-specific ROIs. One potential explanation for these findings is that persons who are more socially detached have less endogenous DA occupying D_2/3R in the VS. This interpretation warrants investigation by future research. These findings may help us better understand the neurochemical basis of attachment.

KEYWORDS:

• TCI
• KSP
• dopamine
• [¹¹C]-(+)-PHNO
• D_2/3R
• attachment

Acknowledgements

The authors would like to thank the PET Centre staff at the Centre for Addiction and Mental Health for technical assistance in data collection. They also thank Wanna Mar, Zhe Feng, Thushanthi Balakumar, Danielle Uy, and Sofia Raitsin for their ongoing support and assistance.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This study was funded by Canadian Institutes of Health Research [grant number MOP-114989]; US National Institute of Health [grant number RO1MH084886-01A2]. Dr. Nakajima reports having received grants from Japan Society for the Promotion of Science and Inokashira Hospital Research Fund and speaker’s honoraria from GlaxoSmith Kline, Janssen Pharmaceutical, Pfizer, and Yoshitomiyakuhin within the past 3 years. Dr. Graff-Guerrerro currently receives research support from the following external funding agencies: Canadian Institutes of Health Research, the US National Institute of Health, and the Mexico Instituto de Ciencia y Tecnologıa para la Capital del Conocimiento en el Distrito Federal (ICyTDF). He has also received professional services compensation from Abbott Laboratories, Gedeon-Richter Plc, and Lundbeck; grant support from Janssen; and speaker compensation from Eli Lilly.